TY - JOUR
T1 - Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients
AU - Marino, Mariapaola
AU - Di Sante, Gabriele
AU - Provenzano, Carlo
AU - Mirabella, Massimiliano
AU - Pani, Giovambattista
AU - Ria, Francesco
AU - Frisullo, Giovanni
AU - Samengo, Daniela Maria
AU - Bartoccioni, Emanuela
PY - 2017
Y1 - 2017
N2 - Abstract
BACKGROUND:
Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a group of MS patients, with amino acids 83-120 being the major epitope. Moreover, a strong correlation between anti-KIR4.183-120 and anti-full-length-protein auto-antibodies titer was reported. However, this finding received limited confirmation.
OBJECTIVE:
Validation of the diagnostic potential of anti-KIR4.183-120 antibodies in 78 MS patients, 64 healthy blood donors, and 42 individuals with other neurological diseases.
METHODS:
Analysis of anti-KIR4.183-120 antibodies by enzyme-linked immunosorbent assay (ELISA) using a mouse antiserum we produced as a new ELISA reliability control. Additionally, evaluation of reactivity against 293-T cells transiently transfected with full-length KIR4.1 by flow cytometry.
RESULTS:
We found antibodies to KIR4.183-120 only in 13 out of 78 (16.6%) MS patients; among these, only 2 were positive for anti-full-length KIR4.1 antibodies.
CONCLUSION:
Employing a new reliability control and a new cytofluorometric assay, we cannot support anti-KIR4.183-120 auto-antibodies as a reliable biomarker in MS.
AB - Abstract
BACKGROUND:
Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a group of MS patients, with amino acids 83-120 being the major epitope. Moreover, a strong correlation between anti-KIR4.183-120 and anti-full-length-protein auto-antibodies titer was reported. However, this finding received limited confirmation.
OBJECTIVE:
Validation of the diagnostic potential of anti-KIR4.183-120 antibodies in 78 MS patients, 64 healthy blood donors, and 42 individuals with other neurological diseases.
METHODS:
Analysis of anti-KIR4.183-120 antibodies by enzyme-linked immunosorbent assay (ELISA) using a mouse antiserum we produced as a new ELISA reliability control. Additionally, evaluation of reactivity against 293-T cells transiently transfected with full-length KIR4.1 by flow cytometry.
RESULTS:
We found antibodies to KIR4.183-120 only in 13 out of 78 (16.6%) MS patients; among these, only 2 were positive for anti-full-length KIR4.1 antibodies.
CONCLUSION:
Employing a new reliability control and a new cytofluorometric assay, we cannot support anti-KIR4.183-120 auto-antibodies as a reliable biomarker in MS.
KW - KIR4.1
KW - auto-antibodies
KW - biomarker
KW - enzyme-linked immunosorbent assay
KW - flow cytometry
KW - multiple sclerosis
KW - KIR4.1
KW - auto-antibodies
KW - biomarker
KW - enzyme-linked immunosorbent assay
KW - flow cytometry
KW - multiple sclerosis
UR - http://hdl.handle.net/10807/106460
U2 - 10.1177/1352458517711275
DO - 10.1177/1352458517711275
M3 - Article
SP - N/A-N/A
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
SN - 1352-4585
ER -